Ligand Pharmaceuticals closes acquisition of Crystal Bioscience
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback
Infographic: The Big Picture 2023 Sustainability Outlook
The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism
Ligand Pharmaceuticals Inc. closed its acquisition of privately held Crystal Bioscience Inc. for an initial consideration of about $25 million in cash.
Crystal is now a wholly owned subsidiary of Ligand.
According to the merger agreement, Crystal shareholders will also receive up to $10.5 million in milestone payments and revenue sharing from existing licensees for a defined period.
